Imagine a world where the devastating effects of Alzheimer's disease can be reversed through an innovative new drug. This scenario may soon become a reality, thanks to groundbreaking research from the Centre for Addiction and Mental Health (CAMH). The study investigates the impact of GL-II-73,
The search for effective treatments for Parkinson's disease has been long and arduous, with researchers globally dedicating countless hours to uncover potential therapies. One promising candidate, exenatide, a GLP-1 drug traditionally used to treat Type 2 diabetes, recently underwent scrutiny
The 2024 Biopharma Technology Landscape report by Benchling, a leading R&D cloud software company, reveals the transformative impact of artificial intelligence (AI) and automation on biopharma research and development (R&D). The report highlights how large biopharma companies are leveraging
The biotech and healthcare sectors in the United Kingdom experienced a remarkable year in 2024, marked by substantial financial investments, significant trends, and notable challenges. Grounded in a report by the UK BioIndustry Association (BIA), this analysis delves into the pivotal investment
The recent moves by the Trump administration have cast a shadow of uncertainty over the biopharma sector, causing significant turmoil among companies relying on federal grants for clinical trials and drug development. The Office of Management and Budget (OMB) issued a memo on Monday that threatened
In a significant development in avian flu research, scientists from the University of Pittsburgh and the NIH Vaccine Research Center have crafted an innovative antibody therapy aimed at tackling the severe H5N1 avian flu virus in monkeys. This new therapy focuses on a broadly neutralizing antibody,
